I agree about the secondaries since the trial is short and as Dr. Rubin I believe pointed out its hard to show benefit in some of these paramaters in short duration. I think even with the small improvement the results are still "good enough" (without the C^2 results) the one thing that is bothersome is TRIUMPH was addon (ETA/PD5) this was mono therapy so I would have expected results in the 40-50 meter+ range to have considered them good. Actually I am an optimist and thought if they got the titration fixed they could get much higher doses and maybe get in the 60 meter improvement neighborhood.
Even though the company claims 3mg is around 30-35 nanograms which is an efficacous dose of Remodulin, from the field Combo study it seemed to me the dose needs to be even higher.
I don't have a position directly but one positive I took from it was the drop out were really low and they may have found a way to dose escalate to make it much more tolerable to be used in other indications. Of course with UTHR's track record it will take them much longer to develop these then one would expect :-).
News 
Market Data 
Discover 
